Skip to main content
. Author manuscript; available in PMC: 2009 Jun 24.
Published in final edited form as: J Control Release. 2008 Mar 21;128(3):224–232. doi: 10.1016/j.jconrel.2008.03.013

Figure 5.

Figure 5

(A) In vivo performances of the formulations. Changes in plasma anti-factor Xa activity after pulmonary administration of LMWH (50 U/kg) in plain and core-modified PLGA microspheres (n=5-6). (B) Effects of plain core-modifying agents and microspheres containing core-modifying agents on the viability of Calu-3 cells. The test samples contained 0.25 mg/ml, 0.025 mg/ml or 0.0025 mg/ml of plain core-modifying surfactants or microspheres containing an equivalent amount of core-modifying agents. Data represent the mean ± standard error of the mean (n=8).